Mutational landscape of homologous recombination-related genes in small-cell lung cancer.

ABSTRACT:

Background

Homologous recombination deficiency (HRD) is a well-known biomarker which could predict poly-ADP ribose polymerase 1 (PARP) inhibitor and platinum drug response. As an aggressive cancer, small-cell lung cancer (SCLC) is sensitive to platinum drugs, but relapse occurs rapidly. Herein, we aim to illustrate the genomic alteration patterns of homologous recombination repair (HRR)-related genes in a Chinese SCLC cohort and further analyze the relationship among HRR gene mutations and known biomarkers of immune checkpoint inhibitor (ICI) response, including tumor mutation burden (TMB) and programmed cell death-ligand 1 (PD-L1) expression.

Methods

Next-generation sequencing (NGS)-based target capture sequencing of 543 cancer-related genes was performed to analyze the gen

SUBMITTER: Wu S 

PROVIDER: S-EPMC9972032 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature